Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04359186 · ClinicalTrials.gov registry record · NA
SCOPE Analytic Treatment Interruption Protocol
A NA study of HIV/AIDS, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT04359186: Recruiting NA study of HIV/AIDS, sponsored by University of California, San Francisco.
NCT04359186 is a NA study of HIV/AIDS that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 40 participants, below the 33,180-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04359186, a NA study of HIV/AIDS, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to understand the interaction between HIV and the host at the earliest stages when HIV medications are paused. Volunteers with HIV will interrupt antiretroviral therapy (ART) and then have intensive studies preformed two to three times per week. Most will resume therapy within three weeks, even if the virus does not rebound during this time.
Primary Outcome
The proportion of participants developing acute retroviral syndrome
Conditions Studied
Interventions
- OTHER Treatment Interruption Arm
Study Locations (1)
California
- University of California San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2028-06 |
| Phase | NA |
What NCT04359186 shows while recruiting
NCT04359186 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 33,180-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower).
The record links to 1 condition, with HIV/AIDS appearing as the primary indexed condition, and to 1 intervention - of which Treatment Interruption Arm is the first listed.
NCT04359186 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04359186 about?
NCT04359186 is a clinical study titled "SCOPE Analytic Treatment Interruption Protocol". The goal of this study is to understand the interaction between HIV and the host at the earliest stages when HIV medications are paused. Volunteers with HIV will interrupt antiretroviral therapy (ART) and then have intensive studies preformed two to three times per week. Most will resume therapy wit...
What is the current status of trial NCT04359186?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2020-10-15. Estimated completion is 2028-06.
What conditions does trial NCT04359186 study?
This clinical trial studies the following conditions: HIV/AIDS.
What interventions are being tested in trial NCT04359186?
The interventions under investigation include: Treatment Interruption Arm (OTHER).
Who is sponsoring clinical trial NCT04359186?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04359186 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV/AIDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04359186's enrollment target sits among peer trials
40 48th of 61 higher than 13 of 61 other HIV/AIDS trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV/AIDS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Mobile Gaming App to Improve Adherence to PrEP
RECRUITING · NA
-
LinkPositively+ A Mobile Health App Delivered Intervention to Improve HIV Care Outcomes Among Black Women Affected by Mental Health and Violence
RECRUITING · NA
-
MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM
RECRUITING · NA
-
MyPEEPS LITE Trial
RECRUITING · NA
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Improving the Organizational Social Context to Address Structural Racism and Discrimination
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI